A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.
Despite the existence of the prophylactic Bacille Calmette-Guérin (BCG) vaccine, infection by Mycobacterium tuberculosis (Mtb) remains a major public health issue causing up to 1.8 million annual deaths worldwide. Increasing prevalence of Mtb strains resistant to antibiotics represents an urgent thr...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC5931632?pdf=render |
| _version_ | 1811236108648841216 |
|---|---|
| author | Stéphane Leung-Theung-Long Charles-Antoine Coupet Marie Gouanvic Doris Schmitt Aurélie Ray Chantal Hoffmann Huguette Schultz Sandeep Tyagi Heena Soni Paul J Converse Lilibeth Arias Patricia Kleinpeter Benoît Sansas Khisimuzi Mdluli Cristina Vilaplana Pere-Joan Cardona Eric Nuermberger Jean-Baptiste Marchand Nathalie Silvestre Geneviève Inchauspé |
| author_facet | Stéphane Leung-Theung-Long Charles-Antoine Coupet Marie Gouanvic Doris Schmitt Aurélie Ray Chantal Hoffmann Huguette Schultz Sandeep Tyagi Heena Soni Paul J Converse Lilibeth Arias Patricia Kleinpeter Benoît Sansas Khisimuzi Mdluli Cristina Vilaplana Pere-Joan Cardona Eric Nuermberger Jean-Baptiste Marchand Nathalie Silvestre Geneviève Inchauspé |
| author_sort | Stéphane Leung-Theung-Long |
| collection | DOAJ |
| description | Despite the existence of the prophylactic Bacille Calmette-Guérin (BCG) vaccine, infection by Mycobacterium tuberculosis (Mtb) remains a major public health issue causing up to 1.8 million annual deaths worldwide. Increasing prevalence of Mtb strains resistant to antibiotics represents an urgent threat for global health that has prompted a search for alternative treatment regimens not subject to development of resistance. Immunotherapy constitutes a promising approach to improving current antibiotic treatments through engagement of the host's immune system. We designed a multi-antigenic and multiphasic vaccine, based on the Modified Vaccinia Ankara (MVA) virus, denoted MVATG18598, which expresses ten antigens classically described as representative of each of different phases of Mtb infection. In vitro analysis coupled with multiple-passage evaluation demonstrated that this vaccine is genetically stable, i.e. fit for manufacturing. Using different mouse strains, we show that MVATG18598 vaccination results in both Th1-associated T-cell responses and cytolytic activity, targeting all 10 vaccine-expressed Mtb antigens. In chronic post-exposure mouse models, MVATG18598 vaccination in combination with an antibiotic regimen decreases the bacterial burden in the lungs of infected mice, compared with chemotherapy alone, and is associated with long-lasting antigen-specific Th1-type T cell and antibody responses. In one model, co-treatment with MVATG18598 prevented relapse of the disease after treatment completion, an important clinical goal. Overall, results demonstrate the capacity of the therapeutic MVATG18598 vaccine to improve efficacy of chemotherapy against TB. These data support further development of this novel immunotherapeutic in the treatment of Mtb infections. |
| first_indexed | 2024-04-12T12:03:15Z |
| format | Article |
| id | doaj.art-2492b61a9de840cdb94a05e96383a78d |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T12:03:15Z |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-2492b61a9de840cdb94a05e96383a78d2022-12-22T03:33:46ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01135e019681510.1371/journal.pone.0196815A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis.Stéphane Leung-Theung-LongCharles-Antoine CoupetMarie GouanvicDoris SchmittAurélie RayChantal HoffmannHuguette SchultzSandeep TyagiHeena SoniPaul J ConverseLilibeth AriasPatricia KleinpeterBenoît SansasKhisimuzi MdluliCristina VilaplanaPere-Joan CardonaEric NuermbergerJean-Baptiste MarchandNathalie SilvestreGeneviève InchauspéDespite the existence of the prophylactic Bacille Calmette-Guérin (BCG) vaccine, infection by Mycobacterium tuberculosis (Mtb) remains a major public health issue causing up to 1.8 million annual deaths worldwide. Increasing prevalence of Mtb strains resistant to antibiotics represents an urgent threat for global health that has prompted a search for alternative treatment regimens not subject to development of resistance. Immunotherapy constitutes a promising approach to improving current antibiotic treatments through engagement of the host's immune system. We designed a multi-antigenic and multiphasic vaccine, based on the Modified Vaccinia Ankara (MVA) virus, denoted MVATG18598, which expresses ten antigens classically described as representative of each of different phases of Mtb infection. In vitro analysis coupled with multiple-passage evaluation demonstrated that this vaccine is genetically stable, i.e. fit for manufacturing. Using different mouse strains, we show that MVATG18598 vaccination results in both Th1-associated T-cell responses and cytolytic activity, targeting all 10 vaccine-expressed Mtb antigens. In chronic post-exposure mouse models, MVATG18598 vaccination in combination with an antibiotic regimen decreases the bacterial burden in the lungs of infected mice, compared with chemotherapy alone, and is associated with long-lasting antigen-specific Th1-type T cell and antibody responses. In one model, co-treatment with MVATG18598 prevented relapse of the disease after treatment completion, an important clinical goal. Overall, results demonstrate the capacity of the therapeutic MVATG18598 vaccine to improve efficacy of chemotherapy against TB. These data support further development of this novel immunotherapeutic in the treatment of Mtb infections.http://europepmc.org/articles/PMC5931632?pdf=render |
| spellingShingle | Stéphane Leung-Theung-Long Charles-Antoine Coupet Marie Gouanvic Doris Schmitt Aurélie Ray Chantal Hoffmann Huguette Schultz Sandeep Tyagi Heena Soni Paul J Converse Lilibeth Arias Patricia Kleinpeter Benoît Sansas Khisimuzi Mdluli Cristina Vilaplana Pere-Joan Cardona Eric Nuermberger Jean-Baptiste Marchand Nathalie Silvestre Geneviève Inchauspé A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. PLoS ONE |
| title | A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. |
| title_full | A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. |
| title_fullStr | A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. |
| title_full_unstemmed | A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. |
| title_short | A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis. |
| title_sort | multi antigenic mva vaccine increases efficacy of combination chemotherapy against mycobacterium tuberculosis |
| url | http://europepmc.org/articles/PMC5931632?pdf=render |
| work_keys_str_mv | AT stephaneleungtheunglong amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT charlesantoinecoupet amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT mariegouanvic amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT dorisschmitt amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT aurelieray amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT chantalhoffmann amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT huguetteschultz amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT sandeeptyagi amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT heenasoni amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT pauljconverse amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT lilibetharias amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT patriciakleinpeter amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT benoitsansas amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT khisimuzimdluli amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT cristinavilaplana amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT perejoancardona amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT ericnuermberger amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT jeanbaptistemarchand amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT nathaliesilvestre amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT genevieveinchauspe amultiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT stephaneleungtheunglong multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT charlesantoinecoupet multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT mariegouanvic multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT dorisschmitt multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT aurelieray multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT chantalhoffmann multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT huguetteschultz multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT sandeeptyagi multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT heenasoni multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT pauljconverse multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT lilibetharias multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT patriciakleinpeter multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT benoitsansas multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT khisimuzimdluli multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT cristinavilaplana multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT perejoancardona multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT ericnuermberger multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT jeanbaptistemarchand multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT nathaliesilvestre multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis AT genevieveinchauspe multiantigenicmvavaccineincreasesefficacyofcombinationchemotherapyagainstmycobacteriumtuberculosis |